Global Assisted Reproductive Technology Market By Product (Instrument, Accessory & Disposable, and Reagents & Media), By Technology (In Vitro-Fertilization, Artificial Insemination, Frozen Embryo Transfer, and Other Technologies), By Procedure (Fresh Donor, Fresh Non-donor, Frozen Donor, and Frozen Non-donor), By End-User (Fertility Clinic, Hospital, Surgical Center, Clinical Research Institute, Other End-Users), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2023-2032
- Published date: Oct 2023
- Report ID: 63178
- Number of Pages: 297
- Format:
- keyboard_arrow_up
Quick Navigation
Report Overview
In 2022, the global assisted reproductive technology market size accounted for USD 31.85 billion and is expected to reach around USD 179.4 billion in 2032. Between 2023 and 2032, this market is estimated to register a CAGR of 19.4%.
Assisted reproductive technology refers to medical procedures that assist in achieving pregnancy when traditional methods are not successful. These procedures can help individuals as well as couples who are struggling with infertility, or those who may be at risk for passing on genetic disorders to their offspring.
ART includes a variety of procedures, such as in vitro fertilization, intrauterine insemination, intracytoplasmic sperm injection, & preimplantation genetic testing, among others. These procedures may involve the use of fertility medications, surgical interventions, or the uses of donated eggs, sperm, or embryos. In addition, the COVID-19 pandemic has increased the demand for ART in various sectors.
Key Takeaways
- The global assisted reproductive technology (art) market is growing with a CAGR of 19.4% during 2023-2032.
- Accessory & disposable-type ART holds the largest market share at 52.3% in 2022.
- In-vitro fertilization is the most lucrative technology segment with an 87% market share in 2022.
- Fresh non-donor procedures are the most lucrative among different procedures, accounting for 40% of the market in 2022.
- Fertility clinics are the dominant end-users, contributing to 40.5% of the market in 2022.
- Technological advancements, such as IVF and ICSI, have improved ART success rates.
- Rising disposable income makes ART more accessible.
- Increasing awareness and government support contribute to growing demand.
- Europe is the most lucrative market with a 39.2% market share.
- Asia Pacific shows rapid growth due to increasing awareness and demand.
Product Analysis
Based on type, the market for assisted reproductive technology is segmented into instruments, accessories & disposable, and reagents & media. Among these types, the accessory & disposable segment is the most lucrative in the global assisted reproductive technology (art) market, with a projected CAGR of 19.4%. The total revenue share of accessory & disposable-type assisted reproductive technology is 52.3% in 2022.
Accessories & disposables include items such as needles, catheters, or culture dishes that are used during ART procedures and are disposed of after use. Instruments, this includes equipment such as incubators, micromanipulators, or imaging systems that are used in ART procedures. Reagents & media include the various chemicals & media that are used to support embryo development as well as culture during ART procedures.
Technology Analysis
By technology, the market is further divided into in-vitro fertilization, artificial insemination, frozen embryo transfer, and other technologies. The in-vitro fertilization segment is estimated to be the most lucrative segment in the global assisted reproductive technology market, with a market share of 87% and a projected CAGR of 19.4%, in 2022.
Also, artificial insemination is another type of assisted reproductive technology that involves placing sperm directly into a woman’s cervix, uterus, or fallopian tubes, with the goal of increasing the chances of fertilization. Frozen embryo transfer is a technique used in IVF embryos that are not immediately used for implantation and can be frozen & stored for later use. Other technologies in the human reproductive technologies market include various techniques such as gamete intrafallopian transfer, zygote intrafallopian transfer, intracytoplasmic sperm injection, and preimplantation genetic testing.
Procedure Analysis
Based on procedure, the market for assisted reproductive technology is segmented into, fresh non-donor, fresh donor, frozen donor, & frozen non-donor. Among these types, the fresh non-donor segment is the most lucrative in the assisted reproductive technology market, with a projected CAGR of 19.4%. The total revenue share of fresh non-donor-type global assisted reproductive technology is 40% in 2022.
Fresh donor cycles are often used when the female partner is unable to produce viable eggs and when there is a risk of genetic transmission of certain diseases. The frozen donor procedure involves using frozen eggs and embryos from a donor or fresh sperm from the male partner or a sperm donor for fertilization.
The frozen Non-Donor procedure involves using frozen eggs or embryos from the female partner and fresh sperm from the male partner for fertilization. Each procedure has its advantages or disadvantages, The most suitable procedure is chosen based on the specific needs and preferences of the couple.
End-User Analysis
Based on end-user, the market is segmented into fertility clinics, hospitals, surgical centers, clinical research institutes, and other end-users. Among these end-users, the fertility clinic segment is estimated to be the most lucrative segment in the global assisted reproductive technology market share, with the largest revenue share of 40.5% and a projected CAGR of 19.4% during the forecast period.
Fertility clinics are specialized medical centers that provide services related to infertility diagnosis & treatment. Hospitals provide a range of healthcare services, including assisted reproductive technology procedures. Surgical centers are specialized facilities that provide outpatient surgical procedures, including some assisted reproductive technology procedures.
Clinical research institutes are dedicated to conducting research studies to develop new treatments & technologies in the field of reproductive medicine. The choice of end-user depends on various factors such as the availability of specialized services, the level of expertise as well as experience of the healthcare providers, and also the cost of the procedure.
Key Market Segments
Based on Type
- Instrument
- Sperm Separation System
- Cryosystem
- Incubator
- Imaging System
- Ovum Aspiration Pump
- Cabinet
- Micromanipulator
- Laser Systems
- Others
- Accessory & Disposable
- Reagents & Media
- Cryopreservation Media
- Semen Processing Media
- Ovum Processing Media
- Embryo Culture Media
Based on Technology
- In Vitro-Fertilization
- Artificial Insemination
- Frozen Embryo Transfer
- Other Technologies
Based on Procedure
- Fresh Donor
- Fresh Non-donor
- Frozen Donor
- Frozen Non-donor
Based on End-User
- Fertility Clinic
- Hospital
- Surgical Center
- Clinical Research Institute
- Other End-Users
Drivers
Technological advancements & rising disposable income in the ART market
Advances in medical technology, such as in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI), have improved the success rates of ART procedures and expanded the types of patients who can benefit from them. Rising disposable income: As disposable income rises, more people are able to afford the high costs of ART procedures, making it a more accessible option for individuals and couples struggling with infertility.
Increasing awareness and government support for the ART market
The awareness of ART options and their success rates is growing among both patients and healthcare providers, leading to increased demand for these services. Governments in some countries provide financial support for ART procedures, making them more accessible to a wider range of patients.
Restraints
There are some ethical & moral concerns surrounding ART procedures, such as the use of donor eggs or sperm, embryo selection, & surrogacy. These concerns can limit the acceptance of these procedures among some patients or healthcare providers. ART procedures can be physically & emotionally demanding for patients, requiring multiple appointments, medications, & procedures. This can be a deterrent for some patients.
Opportunity
Advancements in technology and expansion of the ART market
Ongoing advancements in medical technology, such as genetic testing & embryo selection, are expected to improve the success rates of ART procedures. ART expand the types of patients who can benefit from them. The ART market is expanding beyond traditional infertility treatments to include other areas, such as fertility preservation, egg freezing, and surrogacy. This expansion is creating new opportunities for growth in the market.
Increasing government support and emerging markets
Governments in some countries are providing financial support for ART procedures, making them more accessible to a wider range of patients. There is potential for significant growth in emerging markets, where access to ART treatments is currently limited but demand is increasing.
Trends
Growing demand for surrogacy, Surrogacy is becoming more popular as infertility rates continue to rise, & social norms change. Same-sex couples, single individuals, or those who are unable to carry a pregnancy to term due to medical conditions are turning to surrogacy as a way to have children.
Growing interest in alternative treatments, there is growing interest in alternative treatments such as acupuncture, nutrition, as well as lifestyle changes to improve fertility outcomes. These treatments are being used in conjunction with traditional ART procedures to improve outcomes as well as reduce the physical and emotional toll on patients.
Regional Analysis
Europe is estimated to be the most lucrative market in the global assisted reproductive technology (art) market, with the largest market share of 39.2%, and is expected to register a CAGR of 19.4% during the forecast period. Asia Pacific is a rapidly growing market for assisted reproductive technology, driven by increasing awareness, demand, & investment in reproductive healthcare.
Countries such as China, India, and Japan have large populations and growing middle classes, which are driving demand for infertility treatment services. North America is a mature market for assisted reproductive technology, with high levels of awareness, adoption, & investment in reproductive healthcare. The Middle East & Africa are relatively underdeveloped markets for assisted reproductive technology, with limited access to healthcare services and also cultural or regulatory barriers to adoption.
Key Regions
- North America
- The US
- Canada
- Mexico
- Western Europe
- Germany
- France
- The UK
- Spain
- Italy
- Portugal
- Ireland
- Austria
- Switzerland
- Benelux
- Nordic
- Rest of Western Europe
- Eastern Europe
- Russia
- Poland
- The Czech Republic
- Greece
- Rest of Eastern Europe
- APAC
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- Indonesia
- Malaysia
- Philippines
- Singapore
- Thailand
- Vietnam
- Rest of APAC
- Latin America
- Brazil
- Colombia
- Chile
- Argentina
- Costa Rica
- Rest of Latin America
- Middle East & Africa
- Algeria
- Egypt
- Israel
- Kuwait
- Nigeria
- Saudi Arabia
- South Africa
- Turkey
- United Arab Emirates
- Rest of MEA
Key Players Analysis
The market share of these key players varies depending on the region, product offerings, or competitive landscape. However, these companies are generally recognized as leaders in the assisted reproductive technology market, with strong brand recognition, extensive distribution networks, and a track record of innovation or success.
Market Key Players
- Cosmos Biomedical Ltd.
- Microm U.K. Ltd.
- CooperSurgical, Inc.
- FUJIFILM Irvine Scientific
- Cryolab Ltd.
- Vitrolife AB
- European Sperm Bank
- Bloom IVF Centre
- Merck KGaA
- Ferring B.V.
- Cook Medical Inc.
- Fujifilm Holdings Corporation
- Genea Biomedx
- Thermo Fisher Scientific, Inc.
- Millendo Therapeutics, Inc.
- Oxford Gene Technology
- Progyny Inc.
- Other Key Players
Recent Developments
- In 2020, a Team of researchers in China used CRISPR gene editing technology to genetically modify human embryos, igniting renewed debate and scrutiny around the ethics and safety of embryo editing in assisted reproductive technology.
- In 2019, California passed legislation that made it legal for doctors to donate unused embryos to research, a move that could spur innovation and advancements in the field of assisted reproductive technology.
Report Scope
Report Features Description Market Value (2022) USD 31.85 Bn Forecast Revenue (2032) USD 179.4 Bn CAGR (2023-2032) 19.4% Base Year for Estimation 2022 Historic Period 2016-2022 Forecast Period 2023-2032 Report Coverage Revenue Forecast, Market Dynamics, COVID-19 Impact on assisted reproductive technology market, Competitive Landscape, Recent Developments Segments Covered By Product-Instrument, Accessory & Disposable, and Reagents & Media; By Technology-In Vitro-Fertilization, Artificial Insemination, Frozen Embryo Transfer, and Other Technologies; By Procedure-Fresh Donor, Fresh Non-donor, Frozen Donor, and Frozen Non-donor; By End-User- Fertility Clinic, Hospital, Surgical Center, Clinical Research Institute, and Other End-Users Regional Analysis North America – The US, Canada, & Mexico; Western Europe – Germany, France, The UK, Spain, Italy, Portugal, Ireland, Austria, Switzerland, Benelux, Nordic, & Rest of Western Europe; Eastern Europe – Russia, Poland, The Czech Republic, Greece, & Rest of Eastern Europe; APAC – China, Japan, South Korea, India, Australia & New Zealand, Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam, & Rest of APAC; Latin America – Brazil, Colombia, Chile, Argentina, Costa Rica, & Rest of Latin America; Middle East & Africa – Algeria, Egypt, Israel, Kuwait, Nigeria, Saudi Arabia, South Africa, Turkey, United Arab Emirates, & Rest of MEA Competitive Landscape Cosmos Biomedical Ltd., Microm U.K. Ltd., CooperSurgical, Inc., FUJIFILM Irvine Scientific, Cryolab Ltd., Vitrolife AB, European Sperm Bank, Bloom IVF Centre, Merck KGaA, Ferring B.V., Cook Medical Inc., Fujifilm Holdings Corporation, Genea Biomedx, Thermo Fisher Scientific, Inc., Millendo Therapeutics, Inc., Oxford Gene Technology, Progyny Inc., Other Key Players Customization Scope Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements. Purchase Options We have three licenses to opt for: Single User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF) Frequently Asked Questions (FAQ)
Which region is more appealing for vendors employed in the assisted reproductive technology market?Europe accounted for the highest revenue share of 38.9%. Therefore, the assisted reproductive technology industry in Europe is expected to garner significant business opportunities over the forecast period.
Name the key areas of business for the assisted reproductive technology market.Germany, France, the UK, The US, Canada, Mexico, China, Japan, etc., are key leading areas of operation for the assisted reproductive technology market.
What is assisted reproductive technology Market Size in the Year 2022?In 2022, the global assisted reproductive technology market accounted for USD 31.85 billion and is expected to reach around USD 179.4 billion in 2032.
What is the Assisted Reproductive Technology Market CAGR During the Forecast Period 2022-2032?The Global Assisted Reproductive Technology Market size is growing at a CAGR of 19.4% during the forecast period from 2022 to 2032.Assisted Reproductive Technology MarketPublished date: Oct 2023add_shopping_cartBuy Now get_appDownload Sample - Cosmos Biomedical Ltd.
- Microm U.K. Ltd.
- CooperSurgical, Inc.
- FUJIFILM Irvine Scientific
- Cryolab Ltd.
- Vitrolife AB
- European Sperm Bank
- Bloom IVF Centre
- Merck KGaA Company Profile
- Ferring B.V.
- Cook Medical Inc.
- FUJIFILM Holdings Corporation Company Profile
- Genea Biomedx
- Thermo Fisher Scientific, Inc.
- Millendo Therapeutics, Inc.
- Oxford Gene Technology
- Progyny Inc.
- Other Key Players
- settingsSettings
Our Clients
Single User $4,599 $3,499 USD / per unit save 24% | Multi User $5,999 $4,299 USD / per unit save 28% | Corporate User $7,299 $4,999 USD / per unit save 32% | |
---|---|---|---|
e-Access | |||
Report Library Access | |||
Data Set (Excel) | |||
Company Profile Library Access | |||
Interactive Dashboard | |||
Free Custumization | No | up to 10 hrs work | up to 30 hrs work |
Accessibility | 1 User | 2-5 User | Unlimited |
Analyst Support | up to 20 hrs | up to 40 hrs | up to 50 hrs |
Benefit | Up to 20% off on next purchase | Up to 25% off on next purchase | Up to 30% off on next purchase |
Buy Now ($ 3,499) | Buy Now ($ 4,299) | Buy Now ($ 4,999) |